Biodesix Targets $20M Series D Round

According to a document filed with the SEC, Biodesix has raised half of its goal of $20 million. Funds will be used to further commercialize its VeriStrat test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories